Project Grant R01AR083966
Award Date
4/10/25
Completion Date
3/31/30
Dollars Obligated
$427K
Similar Awards
This federal Project Grant award of $651,662 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to identify key downstream mediators and potential therapeutic targets regulated by the TGF-β pathway in articular cartilage and osteoarthritis (OA) pathogenesis. The research aims to establish the transcription factor NFIA as a crucial regulator of lipid...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $144,362 Project Grant (CFDA 93.846) to The Johns Hopkins University to investigate the critical biological decision-making processes that guide the differentiation of chondrocyte progenitor cells during synovial joint and bone development. The primary objectives are to: 1) determine the antagonistic effects of transcription factors like PITX1 and ATF4 in promoting the expression of articular cartilage...
This $983,329 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research into the roles and functions of the superficial zone cells in mature articular cartilage. The primary objectives are to: 1) characterize the unique properties of superficial zone cells during growth and damage response, 2) directly test the requirement of superficial...
This $1,288,152 Project Grant was awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant will fund research to develop a high-throughput screening method, named "JointSeq", to identify nanoparticles that can target specific cell types in the osteoarthritic joint. The overarching goal is to enable cell-specific delivery of therapeutics to treat...
This $1,476,001 Project Grant was awarded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant aims to determine how adipose (fat) tissue communicates with the knee joint to influence the development and progression of osteoarthritis (OA). The research will investigate three potential mechanisms of inter-organ crosstalk: signaling through soluble secreted factors, cell migration or cell-to-cell mediation, and...
This federal Project Grant award of $571,650, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to repurpose FDA-approved drugs for the treatment of osteoarthritis. The University of Pittsburgh, the prime awardee, will utilize high-throughput screening in microphysiological models, including human stem cell-derived 3D models of cartilage,...
This three-year, $906,000 project grant from the National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases will fund research into obesity-promoting protein malonylation and its role in chondrocyte metabolic dysfunction and osteoarthritis development. Specifically, the grantee - Ohio University - will investigate how obesity accelerates osteoarthritis through "carbon stress," which causes metabolic byproducts to accumulate in cartilage...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), with CFDA number 93.846 Arthritis, Musculoskeletal and Skin Diseases Research, will provide $456,808 to the Buck Institute for Research on Aging to develop innovative mass spectrometry imaging (MSI) technologies for spatially visualizing proteins and glycans in joint tissues. The goal is to advance the understanding of disease progression in osteoarthritis and meniscal...
This Project Grant award of $408,669 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to identify genetic and imaging biomarkers that can predict osteoarthritis (OA) progression and joint pain. The grantee, The Regents of the University of California, San Francisco (UCSF), will leverage expertise in osteocyte biology, deep learning, and statistical...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $123,040.00 to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate the therapeutic role of the NFAT1 transcription factor in osteoarthritis (OA) development. The research aims to evaluate the potential of NFAT1 as a therapeutic target to halt...